# 11. References

[← Previous: Treatment Algorithm](10-treatment-algorithm.md) | [Back to Main](../README.md) | [Next: Appendices →](12-appendices.md)

---

## Primary Guidelines

### 1. ILAE Guidelines and Reports
- **Website:** [ilae.org/guidelines](https://www.ilae.org/guidelines/guidelines-and-reports)
- **Updated Classification of Epileptic Seizures: Position Paper of the ILAE (2025)**
  - [Epilepsia Position Paper](https://onlinelibrary.wiley.com/doi/10.1111/epi.18338) - Beniczky S, et al.
  - [Practical Guide to 2025 Classification](https://onlinelibrary.wiley.com/doi/10.1002/epd2.70110)
  - [ILAE Infographic (2025)](https://www.ilae.org/files/dmfile/ilaeyes-infographic-2025-sz-classifications.pdf)
- Treatment of Seizures in the Neonate: Guidelines and Consensus-based Recommendations (2023)
- Medical Therapies for Epilepsy
- ILAE Classification of Seizures and Epilepsies (2017) - Fisher RS, et al.; Scheffer IE, et al.
- Terminology of medicines used to control seizure disorders: 2024 ILAE Recommendations

### 2. AAN/AES/SMFM Practice Guidelines
- [Practice guideline update: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy](https://www.neurology.org/doi/10.1212/WNL.0000000000005755) (2018, reaffirmed 2024)
- [Practice guideline update: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy](https://www.neurology.org/doi/10.1212/WNL.0000000000005756) (2018, reaffirmed 2024)
- **AAN/AES/SMFM 2024 Joint Practice Guideline: Use of Antiseizure Medications During Pregnancy**
  - [Neurology](https://pubmed.ncbi.nlm.nih.gov/38748979/) - May 2024
  - Key recommendations for ASM use during pregnancy, fetal risk assessment, and preconception counseling

### 3. NICE NG217
- [Epilepsies in children, young people and adults](https://www.nice.org.uk/guidance/ng217) (2022, reaffirmed 2025)
- Comprehensive guidance on diagnosis, treatment, and management

---

## Key Clinical Trials

### 4. SANAD II Trial
- **Citation:** Marson AG, et al. Lancet. 2021
- **Topic:** Lamotrigine vs levetiracetam vs zonisamide for focal epilepsy; Valproate vs levetiracetam for generalized and unclassified epilepsy
- **Key Finding:** Lamotrigine superior to levetiracetam for time to treatment failure in focal epilepsy

### 5. ESETT Trial
- **Citation:** Kapur J, et al. N Engl J Med. 2019
- **Topic:** Fosphenytoin vs valproate vs levetiracetam for established status epilepticus
- **Key Finding:** No significant difference in efficacy among the three agents (45-47% seizure cessation)

---

## New ASM Approvals and Studies

### 6. Ganaxolone (Ztalmy)
- **FDA Approval:** March 2022 for CDKL5 deficiency disorder
- **Mechanism:** Positive allosteric modulator of GABA-A receptors
- **Key Trial:** Marigold Study - significant reduction in major motor seizures

### 7. Fenfluramine (Fintepla)
- **FDA Approvals:** 2020 (Dravet syndrome), 2022 (Lennox-Gastaut syndrome)
- **Mechanism:** Serotonin releasing agent, 5-HT receptor agonist
- **Key Trials:** Study 1 and Study 2 for Dravet; Study 1506 for LGS

### 8. Cenobamate (Xcopri)
- **FDA Approval:** 2019 for focal seizures
- **Mechanism:** Dual mechanism - sodium channel blockade and GABA-A positive modulation
- **Key Finding:** High responder rates (>50% seizure reduction) in drug-resistant focal epilepsy

---

## Pregnancy and Teratogenicity

### 9. Stanford Medicine Study (2024)
- [Newer antiseizure drugs safe for pregnancy](https://med.stanford.edu/news/all-news/2024/12/epilepsy-pregnancy.html)
- **Key Finding:** Lamotrigine and levetiracetam confirmed safe for pregnancy; no difference in verbal abilities at age 6

### 10. Nature Communications 2024
- [Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes](https://www.nature.com/articles/s41467-024-53813-1)
- **Key Finding:** No significant neurodevelopmental risk increase with lamotrigine or levetiracetam

### 11. NEJM 2024
- [Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure](https://www.nejm.org/doi/full/10.1056/NEJMoa2309359)
- **Key Finding:** Valproate 30-40% NDD risk; topiramate 2.5x ID risk; lamotrigine no significant increase

### 12. Teratogenicity Risk with ASM Duotherapy (2024)
- [PubMed 2024](https://pubmed.ncbi.nlm.nih.gov/38340680/)
- **Key Finding:** Lamotrigine + levetiracetam combination 60% lower MCM risk than valproate monotherapy

### 13. MHRA Pregnancy Prevention Programme (June 2024)
- Topiramate and valproate pregnancy prevention requirements
- Enhanced counseling and contraception requirements for women of childbearing potential

---

## Special Populations

### 14. Elderly
- [Pharmacologic Considerations in the Treatment of Older Adults With Epilepsy](https://practicalneurology.com/articles/2024-nov/pharmacologic-considerations-in-the-treatment-of-older-adults-with-epilepsy) - Practical Neurology 2024
- **Key Recommendations:** Prefer levetiracetam, lamotrigine, gabapentin; avoid phenytoin, carbamazepine

### 15. Status Epilepticus
- [Management of convulsive status epilepticus: recent updates](https://pmc.ncbi.nlm.nih.gov/articles/PMC10295829/) - PMC 2023
- [Clinical practice guidelines on the management of status epilepticus in adults](https://epi-care.eu/wp-content/uploads/2024/05/Vignatelli-etal_2024_-Clinical-practice-guidelines-on-the-management-of-status-epilepticus-in-adults.pdf) - EpiCare 2024

---

## Drug Interactions

### 16. CYP3A Induction
- [The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta-analysis](https://onlinelibrary.wiley.com/doi/10.1111/epi.17822) - Epilepsia 2024

### 17. General Drug Interactions
- [Clinically relevant drug interactions with antiepileptic drugs](https://pmc.ncbi.nlm.nih.gov/articles/PMC1885026/) - British Journal of Clinical Pharmacology

### 18. Pharmacogenetics
- [Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1584566/full) - Frontiers in Pharmacology 2025

---

## Additional Resources

### Guidelines and Position Statements

| Organization | Resource |
|--------------|----------|
| **ILAE** | [Medical Therapies for Epilepsy](https://www.ilae.org/patient-care/medical-therapies) |
| **AES** | [Treatment Guidelines](https://aesnet.org/) |
| **Epilepsy Foundation** | [Summary of Anti-Seizure Medications](https://www.epilepsy.com/stories/summary-anti-seizure-medications) |
| **WHO** | Essential Medicines List - Antiepileptic drugs |

### Pharmacology References

| Resource | Description |
|----------|-------------|
| **UpToDate** | Antiseizure medications: Mechanism of action, pharmacology, and adverse effects |
| **Epilepsy Foundation** | Medication information sheets |
| **FDA** | Package inserts and safety communications |

### Pregnancy Registries

| Registry | Website |
|----------|---------|
| **NAAED Pregnancy Registry** | [aedpregnancyregistry.org](http://www.aedpregnancyregistry.org/) |
| **EURAP** | [eurapinternational.org](http://www.eurapinternational.org/) |
| **UK Epilepsy and Pregnancy Register** | [epilepsyandpregnancy.co.uk](https://www.epilepsyandpregnancy.co.uk/) |

---

## How to Stay Updated

1. **ILAE Congress** - Annual/biannual updates on epilepsy management
2. **AES Annual Meeting** - Latest research and guidelines
3. **Epilepsia** - Peer-reviewed journal with practice-changing studies
4. **FDA MedWatch** - Safety alerts and label changes
5. **MHRA** - UK regulatory updates

---

[← Previous: Treatment Algorithm](10-treatment-algorithm.md) | [Back to Main](../README.md) | [Next: Appendices →](12-appendices.md)
